Health ConditionsParkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra and the accumulation of alpha-synuclein within Lewy bodies. The condition is the second most common progressive neurodegenerative disorder, affecting 2% to 3% of people older than 65. PD afflicted more than 8.5 million people globally in 2019, as its prevalence more than doubled during the preceding 25 years.
PD affects approximately 1% of the population above 60 years and is characterized by the progressive loss of dopaminergic neurons and the formation of Lewy bodies in the affected brain areas. By the time a clinical diagnosis is made, more than 50% and up to 80% of the dopaminergic neurons have degenerated.
A pathological feature of Parkinson's disease is the progressive loss of dopaminergic neurons and decreased dopamine (DA) content in the substantia nigra pars compacta. Progressive degeneration of dopaminergic neurons reduces DA content in the SN and striatum and triggers the onset of PD clinical symptoms such as tremor, postural instability, bradykinesia, and muscle rigidity.
Disturbances of DA synthesis, storage, transportation, and metabolism have been shown to promote neurodegeneration of dopaminergic neurons; dopamine is unstable and can undergo oxidation and metabolism to produce multiple reactive and toxic by-products, including reactive oxygen species, DA quinones, and 3,4-dihydroxyphenylacetaldehyde.
Lewy bodies are abnormal aggregates and inclusions of protein that develop inside nerve cells in people with Parkinson's disease; the aggregations usually consist of insoluble fibrillary aggregates containing misfolded proteins, with a protein called alpha-synuclein as the main component.
Alpha-synuclein undergoes misfolding and abnormal aggregation in pathological conditions, with the process involving a transition from its standard soluble form to an aggregated beta-sheet conformation culminating in the formation of Lewy bodies; cytoplasmic structural proteins, complement proteins, ubiquitin, and misfolded alpha-synuclein comprise these neuronal inclusion bodies. Aggregated alpha-synuclein can cause significant neuronal dysfunction by disrupting SNARE complexes essential for vesicle docking and fusion, inducing mitochondrial dysfunction and oxidative stress, and stimulating inflammatory responses in microglia, contributing to neurodegeneration and the eventual death of dopaminergic neurons.
The motor signs of Parkinson's disease are thought to result in large part from reduction of dopamine in the basal ganglia; over recent years, many of the functional and anatomical consequences of dopamine loss in these structures have been identified, both in the basal ganglia and in related areas in the thalamus and cortex, contributing significantly to understanding the link between degeneration of dopamine neurons in the midbrain and the development of parkinsonism.
As the severity of PD increases, the depletion of dopamine leads to further changes in the basal ganglia pathways, including altered function of other basal ganglia neurotransmitters such as glutamate, GABA, and serotonin.
Through the last two decades of research, there has been growing consensus that inflammation-mediated oxidative stress, mitochondrial dysfunction, and cytokine-induced toxicity are mainly involved in neuronal damage and loss associated with PD.
There is substantial evidence for involvement of impaired mitochondrial function in PD; mutations in several genes encoding mitochondria-associated proteins (PINK1, PARK2, and PARK7) are strongly linked to familial forms of PD, and alterations in mitochondrial respiration, dynamics, and quality control mechanisms are common in PD and its associated animal models, with accompanying increases in oxidative stress. Neuronal vulnerability and neurodegeneration in PD is associated with high mitochondrial energy demand and increased oxidative stress in certain cell types, including dopaminergic neurons.
The six-stage Braak system holds that alpha-synuclein pathology begins in the olfactory bulb or outside the central nervous system in the enteric nervous system before ascending the brain stem. The crosstalk between the gut and the brain serves as a route for the spread of PD pathology in a bottom-up or top-down manner.
Numerous clinical trials have identified the characteristics of changed gut microbiota profiles, and preclinical studies in PD animal models have indicated that gut dysbiosis can influence the progression and onset of PD via increasing intestinal permeability, aggravating neuroinflammation, aggregating abnormal levels of α-synuclein fibrils, increasing oxidative stress, and decreasing neurotransmitter production.
An epidemiological study from Denmark has revealed that a full truncal vagotomy is associated with a reduced risk of subsequent PD, leading to recent interest in the possible role of the gut–brain axis in the pathogenesis of PD.
PD usually presents in later life with the cardinal clinical motor features of bradykinesia, resting tremor, and rigidity, often in various combinations, with postural instability emerging later in the disease course as another defining feature; the motor symptoms of PD are typically asymmetric, which helps differentiate it from other Parkinsonian syndromes.
Both non-motor symptoms, such as mood disorders and cognitive impairment, and motor symptoms, such as tremors and rigidity, are indicative of this progressive neurodegenerative disease. These non-motor symptoms contribute significantly to disability and poor quality of life and also strongly predict admission to care homes.
Age is the biggest risk factor for PD, with the median age of onset being 60 years; the incidence of the disease rises with age to 93.1 (per 100,000 person-years) in age groups between 70 and 79 years. Parkinson's disease is more common in older people and men, and a variety of environmental factors have been suggested to explain why, including exposure to neurotoxic agents.
Nearly one-third of all PD cases are familial, a small subset of which appears autosomal dominant; however, the majority exhibit no clear inheritance pattern; autosomal dominant PD is genetically heterogeneous, and the common forms of PD—both familial and sporadic—appear to involve a complex interplay of genetic susceptibility and environmental exposure.
The etiology of Parkinson's disease remains largely unknown, but genetic and environmental factors are believed to play a role. It is insufficient to regard this disorder as primarily caused by a deficiency of dopamine in the substantia nigra; there appears to be a more complex and extensive pathophysiology underlying this, and the nongenetic causes of α-synuclein deposition in the brain are a subject of active research.
Increased risk of Parkinson's disease has been associated with exposure to pesticides, consumption of dairy products, history of melanoma, and traumatic brain injury. Parkinson's disease has been associated with rural living, well-water consumption, and pesticide exposure.
Neuropathologic studies and animal models show that exposure to environmental neurotoxicants can determine progressive damage in the substantia nigra many years before the onset of clinical parkinsonism; PD, like other neurologic diseases related to aging, may be determined by exposures present in the environment early during the life span or even during pregnancy.
In a case-control study of 138,345 patients with incident PD and 276,690 matched controls, an increased risk of PD was associated with a range of risk factors and prodromal features, particularly tremor, restless legs syndrome, and both schizophrenia and bipolar disorder; comorbidities such as diabetes types 1 and 2, epilepsy, sensory skin disturbances, and gastrointestinal disorders; and risk factors such as alcohol misuse and traumatic head injury.
Prodromal features of Parkinson's disease can start more than a decade before typical clinical symptoms allow a diagnosis; these risk factors include well-known genetic or environmental risk factors but also diabetes type 2 or gastric pathology, which may increase the spread of pathology from the enteric nervous system via the vagal nerve to the central nervous system.
Interestingly, smoking, consumption of caffeine, and physical activities are the protective factors of PD. Cigarette smoking has been extensively studied with respect to PD, with mostly consistent results; most of the epidemiological reports are case-control studies showing a reduced risk of developing PD, with larger cohort studies also in agreement. The mechanism underlying the apparent inverse association with smoking is not fully established; nicotine has been hypothesized to have neuroprotective effects, though the evidence does not support promoting smoking for this purpose.
Reduced risk of Parkinson's disease has been reported in association with smoking, caffeine consumption, higher serum urate concentrations. The only intervention that seems justifiable for the primary prevention of Parkinson's disease is the promotion of physical activity, which is likely to be beneficial for the prevention of several chronic diseases.
Coenzyme Q10 is an especially relevant antioxidant in PD research, because it also facilitates function of the mitochondrial transport chain. Mitochondrial complex I deficiencies have been found in post-mortem brains of patients with Parkinson's disease; coenzyme Q10 (CoQ10) is the electron acceptor found in complexes I and II, and is a potent antioxidant.
Scientific evidence: A number of preclinical studies in both in vitro and in vivo models of Parkinson's disease have demonstrated that coenzyme Q10 can protect the nigrostriatal dopaminergic system, and some clinical trials have looked at the neuroprotective effects of coenzyme Q10 in patients with early and mid-stage Parkinson's disease.
The Parkinson Study Group QE3 investigators carried out a phase III RCT on 600 patients from North America, who received placebo, 1200 mg/day, or 2400 mg/day of CoQ10; after 16 months of treatment, no significant differences were found between patients treated with placebo or the two doses of CoQ10. The authors reported in JAMA Neurology that their study of long-term, high-dosage CoQ10 treatment was halted prematurely because it showed no clinical benefit for PD. Previous studies on CoQ10 were mixed: one Phase II trial showed slower functional decline with the compound, another found no beneficial effect. Overall, the current weight of clinical evidence does not support CoQ10 as a disease-modifying or symptom-modifying therapy for PD.
A narrative review of nutrition and lifestyle interventions for PD grouped relevant research into categories that included vitamin D, among others. Nutritional supplementation with omega-3 fatty acids, vitamin D, B vitamins, and coenzyme Q may have potential in the management of PD.
Scientific evidence: For patients with Parkinson's disease, supplementation of vitamin D and B12 may be warranted, and there are concerns regarding supplements that provide more than 100% of the Daily Value for iron and manganese, as well as the timing of vitamin B6 and levodopa. The evidence linking vitamin D status to PD risk is primarily associative; lower serum vitamin D has been observed in PD populations, but whether this is causal or a consequence of reduced sun exposure due to reduced mobility remains unclear. The evidence is currently rated as limited in quality.
A meta-analysis consisting of case-control and cross-sectional studies showed that PD patients had lower folate and vitamin B12 levels (SMD [95%CI]: −0.30[−0.39, −0.22], p < 0.001 for vitamin B12; SMD [95%CI]: −0.20[−0.28, −0.13], p < 0.001 for folate).
Thiamine (B1) deficiency has been linked with neuroinflammation and neurodegeneration, suggesting a role in the progression of PD; an observational study found that 100 mg of B1 administered intramuscularly twice weekly improved PD symptoms within 3 months. A study to determine riboflavin (B2) status among participants with PD found that people with PD had lower serum B2 levels compared to controls; after supplementation with 30 mg of B2 every eight hours, participants reported improved sleep, reasoning, and motivation and reduced depression within two weeks and improved motor function by 44–71% in three months. These findings are preliminary and come from small, non-randomized observations.
A deficiency in B vitamins is associated with neuroinflammation and oxidative stress, for which homocysteine is a biomarker. Linear mixed effects modelling showed that lower baseline urate and higher homocysteine predicted decline in motor function; only higher homocysteine concentrations at baseline predicted declining MoCA (cognitive) scores over 54 months.
Increased vitamin B intake may be associated with decreased risk of PD by reducing plasma homocysteine. However, data on PD risk and dietary sources of these vitamins remain limited, and high-quality interventional trials are lacking.
As neuroinflammation and oxidative stress are recognized factors involved in PD, the beneficial effects of the Mediterranean Diet could rely on the antioxidant and anti-inflammatory properties of this dietary pattern; among the different elements found in this diet, vitamins, omega-3 polyunsaturated fatty acids (ω3-PUFAs), and polyphenols have been largely studied for their protective properties.
Scientific evidence: The evidence for omega-3 supplementation in PD consists primarily of observational data and small mechanistic studies. Nutritional supplementation with omega-3 fatty acids may have potential in the management of PD. Human clinical trial data are limited and have not yet established a definitive clinical benefit; the evidence is considered preliminary.
Reduced risk of Parkinson's disease has been reported in association with higher serum urate concentrations. Urate is an endogenous antioxidant, and observational data consistently report lower serum urate in PD patients relative to controls. Linear mixed effects modelling showed that lower baseline urate predicted decline in motor function. Randomised trials are investigating the possibility that urate may be neuroprotective and thus beneficial in individuals with early Parkinson's disease. Evidence remains epidemiological and investigational; no dietary or supplemental intervention has yet been confirmed to modify PD outcomes through urate elevation.
Dietary supplements that patients with Parkinson's disease have reported taking include coenzyme Q10, creatine, glutathione, vitamin E, and other antioxidants. Given the role of oxidative stress in PD pathology, both vitamins C and E have been studied as potential protective agents. However, large interventional trials have not demonstrated significant disease-modifying benefit from vitamin E supplementation in PD. The evidence is mixed and insufficient to support therapeutic use.
The relationship between PD risk and dietary flavonoid intake was studied in the Health Professional Follow-Up Study (N = 49,287 men) and the Nurses' Health Study (N = 80,336 women), who were followed for 20 to 22 years. These large prospective cohort studies found associations between higher flavonoid intake and reduced PD risk, though such evidence is observational and cannot establish causation.
Traditional use: Mucuna pruriens (M. pruriens), a plant traditionally used in Ayurvedic medicine, contains a significant amount of L-dopa (4%–6%), the primary active component of conventional levodopa therapy—the gold standard treatment for PD. Mucuna has been used in traditional medicine for millennia for a number of medical conditions; it is thought to have anti-inflammatory properties and has been documented in ancient texts to help what sounds like Parkinson's disease.
Scientific evidence: Out of 466 articles identified in a systematic review, 5 clinical trials involving a total of 108 participants (mean age: 60 years) were included; quality assessment rated one study as high quality, one as having some concerns, and three as low quality; despite heterogeneity in M. pruriens interventions, the findings consistently showed improvements in PD symptoms and therapy-related complications, with treatment associated with a shorter time to reach the "on" disease stage, prolonged duration of this stage, and fewer adverse events, with no dyskinesia reported.
M. pruriens shows promise in improving motor symptoms and reducing therapy complications in PD patients; however, current clinical evidence is limited and further high-quality trials are needed to confirm its efficacy and safety. In animal models, M. pruriens seed powder remarkably elevated the endogenous level of L-dopa, dopamine, norepinephrine, and serotonin in the substantia nigra in 6-OHDA-induced PD rat models.
Traditional use: Green tea (Camellia sinensis) has been consumed for millennia in East Asian cultures for its perceived health-promoting properties. Traditional Chinese medicine texts document its use as a tonic and anti-fatigue beverage. Its application to neurological symptoms was not formalized in traditional monographs, but epidemiological observations in tea-drinking populations sparked modern scientific interest.
Scientific evidence: Epigallocatechin-3-gallate (EGCG), an abundant polyphenolic component derived from green tea extract, possesses versatile bioactivities; during the last decade, EGCG was shown to be effective in experimental models of Parkinson's disease, and several experimental studies have suggested that it has pleiotropic neuroprotective effects.
Numerous findings suggest that EGCG targets protein misfolding and aggregation, a common pathological mechanism in many neurodegenerative diseases; several studies have shown that EGCG interacts with misfolded proteins such as α-synuclein, linked to Parkinson's disease.
In vitro experiments suggested that green tea polyphenols (GTP) could protect dopamine neurons; EGCG was suggested to reduce neuronal cell death and induce nitric oxide synthase (NOS) expression in an MPTP mouse model of PD, providing further evidence for the neuroprotective role of green tea. However, although EGCG has good pharmacological and biological activity, the bioavailability of oral EGCG is relatively poor; the highest plasma concentration of EGCG was only 0.15 µM after a human ingested two cups of green tea, and most of the EGCG was not absorbed. As of current literature, human clinical trials specifically in PD populations are limited, and the evidence remains largely preclinical.
Traditional use: Curcumin is the principal bioactive polyphenol in turmeric (Curcuma longa), a rhizome used extensively in Ayurvedic and traditional Chinese medicine for inflammatory conditions, wound healing, and digestive disorders. Turmeric preparations were not specifically documented for tremor or movement disorders in classical Ayurvedic texts, but its general anti-inflammatory application in neurological conditions has been described in folk traditions of South and Southeast Asia.
Scientific evidence: Among neuroprotective phytochemicals, phenolic molecules are of particular interest since most can target both amyloid aggregation and oxidative stress, as confirmed by numerous studies with phenolic compounds such as EGCG, curcumin, resveratrol, quercetin, and oleuropein. Curcumin's evidence in PD is confined predominantly to cell culture and animal model studies demonstrating inhibition of α-synuclein aggregation and oxidative stress reduction. Human clinical trial data specific to PD are lacking, and poor bioavailability is a recognized limitation. The evidence is currently preclinical only.
Traditional use: Coffee and caffeine-containing beverages have been used globally for centuries as stimulants. No traditional medicinal system specifically attributed neuroprotective effects to caffeine, though its stimulant properties were widely recognized.
Scientific evidence: Smoking and coffee drinking have consistently been identified to have protective associations with PD. Randomised trials are investigating the possibility that caffeine may be neuroprotective and beneficial in individuals with early Parkinson's disease. Epidemiological data across multiple cohort studies have consistently shown an inverse association between caffeine consumption and PD incidence. The biological mechanism proposed involves adenosine receptor antagonism. However, clinical trials designed to modify PD outcomes through caffeine administration have yielded mixed results, and caffeine is not established as a treatment for PD.
Diet induces changes in the gut microbiome, with Western diet evoking and Mediterranean diet preventing neuroinflammation and neurodegeneration associated with PD. As neuroinflammation and oxidative stress are recognized factors involved in PD, the beneficial effects of the Mediterranean Diet could rely on the antioxidant and anti-inflammatory properties of this dietary pattern.
Traditional epidemiological data generally suggest a diet high in dairy, meat, refined pastries, and fried food is associated with an increased risk of PD diagnosis, while a diet high in fresh fruits and vegetables, whole grains, legumes, nuts, and seeds is associated with a reduced risk of diagnosis. The collection of research related to diet patterns was assigned a GRADE of fair (II) due to utilizing study designs that are less appropriate for interventions (cohort, crossover) and small sample sizes.
The MIND diet has been linked with prevention of Alzheimer's disease and cognitive decline but has not been fully assessed in the context of Parkinson's disease; the objective of one study was to determine whether MIND diet adherence is associated with the age of Parkinson's disease onset in a manner superior to that of the Mediterranean diet.
The Mediterranean (MEDI) and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets have been associated with a reduced risk of Parkinson's disease diagnosis; however, studies evaluating whether these diets are associated with disease progression in those patients already diagnosed are lacking.
Data were consistent with findings of recent studies that suggested the MIND diet was more strongly correlated with reduced risk and slower progression of parkinsonism compared to the MEDI diet. The MIND diet was most significantly associated with later age-at-onset in the female subgroup, more than three times greater than that of the male or MEDI diet subgroups, suggesting that the dietary components in the MIND diet (e.g., leafy green vegetables and berries) may potentially be more beneficial for delaying the onset of motor symptoms in female populations.
A systematic review revealed several consistent patterns in the gut microbiota of PD patients, including reduced microbial diversity and specific taxonomic alterations, including a drop in Firmicutes. Therapeutic strategies that function by reversing gut dysbiosis and mitochondrial dysfunction may prove beneficial to treat PD pathology.
A ketogenic diet, characterized by low carbohydrate and high fat with adequate protein, is receiving acceptance as a potential therapy for PD. However, no study has yet explored the effects of ketogenic diet on gut microbiome in PD patients. Evidence for the ketogenic diet in human PD is currently minimal.
The only intervention that seems justifiable for the primary prevention of Parkinson's disease is the promotion of physical activity, which is likely to be beneficial for the prevention of several chronic diseases. Physical activity has also been associated with modulation of dopaminergic pathways in the brain. Multiple studies have examined exercise programs—including aerobic training, resistance exercise, dance, and tai chi—as adjunctive approaches for managing PD symptoms, with generally positive findings on motor function, balance, and quality of life, though these studies are typically small and heterogeneous.
A well-documented dietary concern in PD pharmacotherapy is the interaction between dietary protein and the absorption of levodopa. Large neutral amino acids compete with levodopa for transport across the blood-brain barrier. There are concerns regarding the timing of vitamin B6 and levodopa. Dietary redistribution of protein intake (e.g., reducing protein consumption at breakfast and lunch) is discussed in the clinical nutrition literature as a practical strategy, though evidence from controlled trials is limited.
Research on stress management with regard to PD was lacking, with only one study utilizing yoga as the intervention. Sleep disturbance—particularly REM sleep behavior disorder—is recognized as a prodromal feature of PD. Rapid eye movement sleep disorder is among the well-established risk factors contributing to the development of PD.
Acetyl-L-Carnitine (ALCAR) has been investigated in Parkinson's disease for its mitochondrial-protective and antioxidant properties. Preclinical studies show it protects dopaminergic neurons against neurotoxin-induced damage. Small clinical studies suggest potential benefit in neuroprotection and symptom management, though large-scale RCTs are lacking.
A 2022 peer-reviewed PMC study (University of Tsukuba) found that amber extract protects human dopaminergic neuronal cells against 6-hydroxydopamine-induced apoptosis in a PD cell model, acting via ROS reduction and autophagy promotion. Evidence is preclinical only.
The ScienceDirect pharmacological overview of anemarrhena lists Parkinson's disease as a therapeutic target alongside Alzheimer's disease. Sarsasapogenin and mangiferin show neuroprotective activity in relevant preclinical models, including protection against neurotoxin-induced neurodegeneration.
Evidence for Parkinson's disease is currently preclinical and mechanistic: astaxanthin has been shown in cell-based and animal studies to modulate oxidative stress, neuroinflammation, and apoptosis in dopaminergic neurons. A 2025 review (Frontiers in Aging Neuroscience) confirms potential neuroprotective effects in PD models, but no human RCTs in PD patients have been completed.
Baicalein, a bioactive flavone from Scutellaria baicalensis (Baikal skullcap), has demonstrated consistent neuroprotective effects in animal models of Parkinson's disease. A 2020 systematic review and meta-analysis of 20 preclinical studies confirmed significant improvements in motor and dopaminergic outcomes. Clinical translation is underway but human trial data remain limited.
Piperine inhibits MAO-B (the enzyme that degrades dopamine), crosses the blood-brain barrier, and protects dopaminergic neurons in multiple animal and cell models of Parkinson's disease. In rotenone-induced neurotoxicity models, piperine restored mitochondrial function in neuronal cells. Evidence is entirely preclinical.
Broad beans (Vicia faba) contain natural L-DOPA and have documented clinical evidence of producing motor improvement in Parkinson's disease patients. Small clinical studies show consumption of 250 g cooked broad beans raises plasma L-DOPA to therapeutic levels, improving motor performance in PD patients.
At least six large prospective epidemiological studies have established an inverse association between caffeine consumption and risk of developing Parkinson's disease. The mechanism involves A2A adenosine receptor antagonism, which may confer neuroprotection against dopaminergic neurodegeneration. Clinical evidence for slowing disease progression is emerging but not yet conclusive.
BCP has protected dopaminergic neurons from MPTP-induced death in multiple mouse models via antioxidant (NQO1, Nrf2), anti-inflammatory, and CB2-mediated neuroprotective mechanisms. Multiple independent preclinical studies support this.
Catalase activity is consistently reduced in the blood of Parkinson's disease (PD) patients compared to controls, as confirmed by multiple meta-analyses. The substantia nigra in PD is under intense oxidative stress, and H₂O₂—the direct substrate of catalase—is generated in excess through dopamine metabolism. Experimental catalase mimetics show neuroprotective properties in animal models.
EGCG has neuroprotective effects relevant to Parkinson's disease through inhibition of dopaminergic neuron apoptosis, mitochondrial protection, and reduction of neuroinflammation. Epidemiological evidence links tea consumption to reduced PD risk, and EGCG's effects on PD models have been examined in clinical trials.
Chrysin demonstrates neuroprotective effects in multiple Parkinson's disease (PD) models, protecting dopaminergic neurons in the substantia nigra, inhibiting monoamine oxidase B (MAO-B), and restoring striatal dopamine. It reduces motor and cognitive deficits in 6-OHDA and MPTP animal models. All evidence is preclinical.
Citicoline (CDP-choline) has been studied in Parkinson's disease for its ability to increase dopamine synthesis and inhibit dopamine reuptake, supporting nigrostriatal function. A meta-analysis reviewed seven clinical studies, though heterogeneity in outcome measures limited conclusions. It is recognized by the American Parkinson Disease Association (APDA) as having some evidence for PD.
CoQ10 has been extensively studied in Parkinson's disease based on evidence of mitochondrial Complex I deficiency in PD patients. Phase II trials showed dose-dependent slowing of functional decline; however, a large Phase III RCT (QE3) failed to confirm disease-modifying benefit. Meta-analyses show it is safe but does not significantly improve motor UPDRS scores versus placebo.
Cowage seed (Mucuna pruriens) contains 4–6% natural L-DOPA, the gold-standard pharmacotherapy for Parkinson's disease. A 2024 systematic review of 5 clinical trials (n=108) found consistent improvements in PD motor symptoms and therapy complications with shorter off-periods and less dyskinesia versus standard levodopa. Ayurvedic traditional use for parkinsonism predates modern medicine.
Creatine was investigated in Parkinson's disease in multiple trials based on its mitochondrial-supportive and neuroprotective properties. A large NINDS-sponsored Phase III NET-PD trial of creatine monohydrate (10 g/day) in early PD was stopped for futility in 2013. Prior Phase II results had been mixed but suggestive, and the APDA notes clinical trials showed no benefit.
Curcumin, the principal bioactive polyphenol in turmeric, has been studied in Parkinson's disease for its ability to inhibit α-synuclein aggregation, reduce neuroinflammation, and modulate oxidative stress. A 2025 systematic review identified two RCTs and one cohort study in PD patients. Preclinical evidence is strong, but clinical translation is hampered by poor bioavailability.
DHA, the primary omega-3 fatty acid in brain tissue, has been studied in Parkinson's disease for its neuroprotective and anti-neuroinflammatory properties. Small clinical studies suggest omega-3 supplementation (including DHA) may modestly improve UPDRS scores in PD patients. Epidemiological data link higher fish oil/omega-3 intake with reduced PD risk.
EGCG, the major polyphenol in green tea, has demonstrated neuroprotective effects in multiple experimental PD models through inhibition of α-synuclein aggregation, MAO-B inhibition, antioxidant activity, and iron chelation. Epidemiological studies link regular green tea consumption to reduced PD risk. Robust clinical trials specific to EGCG in PD are limited.
Multiple preclinical studies demonstrate eucommia extracts protect dopaminergic neurons against MPTP/MPP+ toxicity (standard Parkinson's models), with anti-neuroinflammatory effects via p38/JNK-Fosl2 pathway regulation. A 2025 zebrafish study identified specific anti-PD active constituents in eucommia leaves acting via 4E-BP1 upregulation. No human clinical trials exist.
Fava beans (Vicia faba) naturally contain L-DOPA (0.5% fresh, 0.07% dried), the gold standard pharmacological treatment for Parkinson's disease. Clinical case reports and small studies show significant motor improvement in PD patients consuming cooked fava beans. L-DOPA was first isolated from fava beans by Guggenheim in 1913.
Ferulic acid has demonstrated neuroprotection in multiple Parkinson's disease animal models by reducing dopaminergic neuron loss, attenuating neuroinflammation, and activating the Nrf2/ERK1/2-dependent antioxidant pathway. It reinstates mitochondrial dynamics through PGC1α modulation in 6-OHDA-lesioned rats and protects against MPTP/MPP+-induced oxidative stress. Human clinical evidence is currently limited to the preclinical-to-translational stage.
Fisetin protects dopaminergic neurons against MPTP-induced degeneration in mouse PD models, modulates gut microbiota through the gut-brain axis, restores proteasome activity, and reduces alpha-synuclein pathology. One human case-control study showed dietary fisetin-containing food improved PD motor symptoms.
Geniposide and genipin from Gardenia jasminoides have demonstrated neuroprotective effects against dopaminergic neuron loss in MPTP-induced Parkinson's disease mouse models, mediated by anti-inflammatory and anti-apoptotic mechanisms. Crocin reversed depression-like behavior in a PD mouse model via VTA-mPFC dopaminergic pathway modulation. Evidence is entirely preclinical.
GE and gastrodin have been studied in 6-OHDA Parkinson's disease models, showing neuroprotective effects and reduction of L-DOPA-induced dyskinesia. Gastrodin is listed among compounds used clinically in China for Parkinson's syndrome. Multiple preclinical studies support dopaminergic neuroprotection.
Gastrodin, the primary bioactive glycoside of Gastrodia elata (a Chinese medicinal herb used in traditional medicine for neurological conditions), has shown neuroprotective effects in multiple PD animal models. It protects dopaminergic neurons, reduces neuroinflammation, and maintains dopamine homeostasis. Research is primarily preclinical with growing mechanistic clinical interest.
Ginkgo biloba extract (EGb761) has been studied in both animal models and clinical settings for Parkinson's disease. Animal studies consistently show neuroprotection of dopaminergic neurons via MAO-B inhibition and antioxidant activity. A clinical RCT assessed its efficacy in drug-induced parkinsonism. A 2013 systematic review of 10 controlled animal studies confirmed neuroprotective effects.
GPC has limited but documented human evidence for improving cognitive and neuropsychological symptoms in Parkinson's disease patients with dementia, used adjunctively to standard dopaminergic therapy. The plausible mechanism involves cholinergic augmentation in a disease where both dopaminergic and cholinergic systems are impaired. Evidence quality is low and no current clinical guidelines recommend it for PD.
Green tea and its polyphenols (primarily EGCG) have been associated with reduced Parkinson's disease risk in multiple epidemiological studies. Meta-analyses of population studies show regular tea consumption reduces PD risk. Mechanistically, green tea catechins protect dopaminergic neurons through antioxidant, anti-inflammatory, and α-synuclein inhibiting effects.
Hericium erinaceus (lion's mane mushroom) contains hericenones and erinacines that stimulate nerve growth factor (NGF) synthesis, with established neuroprotective properties relevant to Parkinson's disease. Preclinical studies show it attenuates dopaminergic neurodegeneration and reduces α-synuclein pathology. Clinical evidence is preliminary.
Hesperidin has been studied extensively in preclinical Parkinson's disease models. It protects dopaminergic neurons in the substantia nigra, modulates serotonergic and kappa-opioid receptors, enhances dopamine and its metabolites, and reduces oxidative stress and neuroinflammation. Human clinical data are lacking; evidence is currently preclinical.
A rodent study using the 6-OHDA unilateral striatal injection model of Parkinson's disease found that chronic oral treatment with HMR/lignan slowed the progression of nigrostriatal dopaminergic terminal degeneration and improved motor performance. Anti-inflammatory and antioxidant mechanisms are implicated.
In a 6-OHDA rat model of Parkinson's disease, chronic HMR treatment reduced striatal neuroinflammation, decreased microglial and astrocyte activation markers, and attenuated motor deficits, though it did not significantly increase dopaminergic neuronal survival. HMR and its metabolites have been shown to reach brain tissue after oral dosing. Evidence is entirely preclinical.
Multiple preclinical studies demonstrate that gypenosides protect dopaminergic neurons in rodent models of Parkinson's disease (6-OHDA and MPTP models). Additionally, gypenosides attenuate L-DOPA-induced dyskinesia in animal models. No human clinical trial has been conducted.
A pilot human study found that adding 1.5 g/day L-carnosine to standard L-DOPA therapy produced ~36% improvement in Parkinson's clinical symptoms versus ~16% with medication alone. Preclinical evidence shows carnosine reduces oxidative stress, inhibits alpha-synuclein aggregation, and is neuroprotective in PD models. Larger trials are absent.
Glutathione (GSH), the brain's primary antioxidant, is significantly depleted in the substantia nigra of Parkinson's disease patients. Intravenous glutathione administration in small clinical trials has shown symptom improvement in PD. Direct supplementation and precursor strategies (NAC) have been studied, though oral bioavailability of L-glutathione to the brain is limited.
L-methionine activates methionine sulfoxide reductase A/B and supports glutathione biosynthesis, both of which counteract the oxidative stress and mitochondrial dysfunction central to Parkinson's pathology. An in vitro study using a 6-OHDA dopaminergic neuron model demonstrated that L-methionine protected against oxidative stress and mitochondrial damage. However, L-methionine can competitively reduce levodopa absorption across the blood-brain barrier, an established clinical concern.
Phenylalanine metabolism is measurably altered in Parkinson's disease patients, with reduced tyrosine-to-phenylalanine ratios observed in serum. Mendelian randomization and metabolomic studies have examined causal and associative relationships. L-phenylalanine's role as a dopamine precursor (via tyrosine) is particularly relevant given the dopaminergic deficit in PD.
Altered levels of L-serine and D-serine have been documented in postmortem brain tissue and cerebrospinal fluid of Parkinson's disease (PD) patients, and preclinical studies demonstrate neuroprotective effects of L-serine in PD models. L-serine treatment has been shown to offer beneficial effects for dopaminergic neuron survival in preclinical settings, though no human clinical trial targeting PD specifically has been completed.
Lion's Mane (Hericium erinaceus) contains erinacines and hericenones that stimulate NGF production and have demonstrated neuroprotective effects in preclinical Parkinson's disease models. Erinacine A increases striatal dopamine levels in animal studies. Preliminary clinical evidence from neurological trial settings supports safety and potential neuroprotective benefit.
Preclinical models and pilot human trials support lithium as a potential neuroprotective agent in Parkinson's disease (PD), with evidence of reduced neuroinflammation, α-synuclein pathology, and a biomarker of axonal injury. A 2023 pilot clinical trial and ongoing phase 1b trials are investigating low-dose lithium, including the orotate formulation as a comparator.
Luteolin is neuroprotective in multiple Parkinson's disease cell and animal models, protecting dopaminergic neurons from MPP+, 6-OHDA, and manganese neurotoxicity via Nrf2 activation, mitochondrial protection, and neuroinflammation suppression. Evidence is preclinical; clinical data involve the PEA+luteolin combination.
Emerging clinical interest in MCT for Parkinson's disease (PD) is based on evidence that cerebral glucose hypometabolism occurs in PD as in Alzheimer's, and that ketone bodies may support dopaminergic neuron function. An ongoing open-label trial (NCT04322461) is evaluating 50 g/day MCT with supervised exercise in 20 AD or PD patients. Decanoic acid has shown preclinical promise in reducing oxidative stress relevant to neurodegeneration.
Melatonin, the pineal hormone with potent antioxidant and neuroprotective properties, is often studied in Parkinson's disease. Sleep disturbances are among the most common non-motor symptoms of PD, and melatonin has evidence for improving sleep in PD patients. Additionally, preclinical studies demonstrate it protects dopaminergic neurons from oxidative damage.
N-Acetyl Cysteine (NAC) raises brain glutathione levels and has been studied in Parkinson's disease as a neuroprotective antioxidant. A pilot clinical trial (Thomas Jefferson University, 2019) showed NAC increased dopamine transporter binding on DaTSCAN and significantly improved UPDRS scores in PD patients. Larger trials are needed.
Naringenin (naringin's aglycone) exerts neuroprotective effects in rotenone and other Parkinson's disease animal models by increasing DJ-1 and chaperone-associated E3 ligase expression, protecting dopaminergic neurons in the substantia nigra. Naringin may aid dopaminergic neuron recovery after injury. Evidence is entirely preclinical.
Two phase I randomized controlled trials have directly tested NR in Parkinson's disease patients. The NADPARK study (n=30, 1,000 mg/day for 30 days) showed NR significantly increased cerebral NAD+ levels and was associated with mild clinical improvement. A separate RCT at 3,000 mg/day for 4 weeks also showed significant clinical symptom improvement. A larger 400-person 1-year trial (NOPARK) is ongoing.
Omega-3 fatty acids (EPA and DHA) have been investigated in Parkinson's disease for their anti-neuroinflammatory and neuroprotective properties. Small clinical studies report improvement in UPDRS scores. A real-world PD patient survey found omega-3/fish oil among the most commonly used and most symptom-improving supplements in PD.
Tenuigenin, a major active component of P. tenuifolia, protects dopaminergic neurons from MPTP-induced damage in a mouse Parkinson's disease model by suppressing NLRP3 inflammasome activation in microglia. Other PT compounds protect against 6-OHDA-induced injury in dopaminergic cell lines.
Multiple peer-reviewed preclinical studies document that Polygala root constituents (tenuigenin, Polygalae radix extract) protect dopaminergic neurons from toxin-induced injury in validated Parkinson's disease models, suppress NLRP3 inflammasome activation, and improve motor impairment. Evidence is preclinical, not clinical.
In preclinical models, PQQ confers neuroprotection in rotenone- and 6-OHDA-induced Parkinson's disease models by preserving mitochondrial membrane potential, scavenging ROS, and protecting dopaminergic neurons. No human RCT in Parkinson's patients has been completed; evidence is preclinical but mechanistically well-characterized.
Resveratrol, a polyphenol from grapes and red wine, has demonstrated neuroprotective effects in Parkinson's disease models by activating SIRT1, reducing oxidative stress, inhibiting neuroinflammation, and protecting dopaminergic neurons. Preclinical studies show it inhibits LPS-induced neuroinflammation and protects DA neurons in 6-OHDA rodent PD models. Clinical evidence is still early.
Multiple epidemiological studies report an inverse association between coffee consumption and Parkinson's disease (PD) risk, with an optimal protective dose around 3 cups per day. Robusta coffee's high caffeine and chlorogenic acid content underpin these neuroprotective associations. Caffeine blocks adenosine A2A receptors in the basal ganglia, a validated target in PD pathophysiology.
Rosmarinic acid has demonstrated neuroprotective effects in multiple preclinical Parkinson's disease models (MPTP, rotenone, 6-OHDA), protecting dopaminergic neurons via antioxidant, anti-neuroinflammatory, and mitochondrial-protective mechanisms. RA reduces α-synuclein accumulation and HMGB1/TLR4/NF-κB neuroinflammatory signaling in PD models. No human clinical trials for RA in PD have been published.
Rutin shows neuroprotective effects in MPTP-induced Parkinson's disease animal models by preserving dopaminergic neurons, reducing neuroinflammation, and improving motor and memory deficits. Mechanisms include downregulation of PD-linked proapoptotic genes and restoration of mitochondrial function.
SAMe levels are significantly depleted in levodopa-treated Parkinson's disease (PD) patients, as levodopa metabolism via COMT consumes SAMe and elevates homocysteine. An open-label clinical trial in 13 depressed PD patients found that SAMe at doses of 800–3600 mg/day for 10 weeks produced at least 50% improvement on the Hamilton Depression Scale in 10 of 11 completers. Preclinical data in 6-OHDA rat models show SAMe reduces dopaminergic neuronal loss and improves motor coordination. The evidence is scientifically grounded but limited to small, uncontrolled studies.
Schisandrin B shows neuroprotective effects in the 6-OHDA-induced Parkinson's disease rodent model by inhibiting miR-34a-mediated negative modulation of the Nrf2 pathway. Schisandra chinensis lignans are identified in comprehensive reviews as having potential to combat Parkinson's disease via oxidative stress reduction and neuroinflammation modulation.
Silymarin demonstrates neuroprotection in MPTP mouse models of Parkinson's disease, preserving dopaminergic neurons and striatal dopamine levels. Proposed mechanisms include antioxidant, anti-inflammatory, and anti-apoptotic activity in the substantia nigra. Human clinical trial data for Parkinson's disease specifically is not yet established; evidence is currently preclinical.
SPMs reduce dopaminergic neuron loss and neuroinflammation in preclinical Parkinson's disease models. Neuroinflammation and microglial activation are established PD pathomechanisms that SPMs target. Reduced SPM biosynthesis capacity has been associated with PD-relevant neurological deterioration.
Sulforaphane is neuroprotective against dopaminergic neuron loss in Parkinson's disease models via Nrf2 activation, CBS-H2S axis modulation, mitophagy induction, and neuroinflammation suppression. Reviewed as a potential therapeutic in multiple peer-reviewed analyses; human clinical trials are ongoing.
Taurine demonstrates neuroprotective effects in animal models of Parkinson's disease, inhibiting microglial NADPH oxidase activation, protecting dopaminergic neurons, and improving motor and cognitive outcomes. The evidence base is entirely preclinical; no human PD-specific RCTs have been conducted.
Preclinical and mechanistic reviews identify pterostilbene as a neuroprotective agent in Parkinson's disease models, acting by restoring mitochondrial retrograde signaling, inhibiting NF-κB, and protecting dopaminergic neurons. No human clinical trials in PD have been conducted.
UA's anti-inflammatory, antioxidant, and mitophagy-enhancing properties are mechanistically highly relevant to Parkinson's disease (PD). Preclinical studies show UA preserves dopaminergic neurons, inhibits α-synuclein aggregation, and suppresses neuroinflammation. The Buck Institute is conducting dedicated UA PD research; however, PD-specific human trial data are limited to early-phase work.
Velvet bean seeds contain 4–6% L-DOPA by weight, making them a natural levodopa source for Parkinson's disease. Multiple small clinical trials show comparable or superior motor improvement versus standard levodopa/carbidopa, with faster onset and fewer dyskinesias. A 2025 systematic review of five clinical trials (108 participants) confirmed these findings. The seed likely exerts additional benefit beyond L-DOPA content alone, through antioxidant and anti-neuroinflammatory mechanisms.
An open-label trial (2003) found that high-dose riboflavin supplementation combined with dietary red meat elimination improved motor function in Parkinson's disease patients. Riboflavin is a cofactor for pyridoxine phosphate oxidase, required to activate vitamin B6—itself linked to PD risk reduction. A 2024 gut microbiota meta-analysis identified riboflavin and biotin depletion as consistent features of PD gut microbiome.
Vitamin D deficiency is significantly more prevalent in Parkinson's disease patients than in healthy controls, with a meta-analysis of 63 studies confirming lower vitamin D levels and higher odds of deficiency in PD. Cohort data suggest sufficient vitamin D may reduce PD risk. Supplementation studies show modest, non-significant improvements in motor outcomes.
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D, with consistent evidence of deficiency in Parkinson's disease patients. Observational studies link higher serum 25(OH)D3 levels with lower PD incidence. Small RCTs of D3 supplementation have been conducted in PD with modest motor improvement signals.
Bacopa is studied for anti-Parkinsonian potential based on its neuroprotective profile. Animal model evidence shows protection against dopaminergic neurodegeneration, reduced α-synuclein aggregation, and nigrostriatal protection against MPTP-induced parkinsonism. No human clinical trials in Parkinson's disease patients have been published.
Preclinical animal evidence shows Boswellia serrata extract protects nigrostriatal dopaminergic neurons and improves motor impairments in a 6-OHDA rat model of Parkinson's disease. No human clinical trial has been conducted in Parkinson's patients. Traditional Ayurvedic texts also list psychological and movement-disorder applications.
Bacopa monnieri is studied for Parkinson's neuroprotection primarily in preclinical models, with evidence for reduced dopaminergic neuronal degeneration, α-synuclein aggregation inhibition, and oxidative stress reduction. Traditional use in neurological disorders and preclinical promise exist, but human clinical data are absent.
Go back